MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 17, Issue 8, 2013, Pages 1399-1405

  Liu, Wen Jing ^a   Zhao, Yu Pei ^a   Zhang, Tai Ping ^a   Zhou, Li ^a   Cui, Quan Cai ^a   Zhou, Wei Xun ^a   You, Lei ^a   Chen, Ge ^a   Shu, Hong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Expression; MiR 155; Mut L homologue 1; Pancreatic cancer; Survival

Indexed keywords

MESSENGER RNA; MICRORNA; MIRN155 MICRORNA, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CHEMISTRY; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84880132922     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2230-5     Document Type: Article

References (35)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-17.
2. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 2010; 16: 5107-13.
3. Mackay HJ, Cameron D, Rahilly M, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol. 2000; 18: 87-93.
4. Kruschewski M, Noske A, Haier J, et al. Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? Clin Exp Metastasis. 2002; 19: 71-7.
5. Kishi K, Doki Y, Yano M, et al. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003; 9: 4368-75.
6. Uehara H, Miyamoto M, Kato K, et al. Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma. J Surg Oncol. 2005; 92: 109-15.
7. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 2008; 99: 375-82.
8. Sinha S, Singh RK, Alam N, et al. Frequent alterations of hMLH1 and RBSP3/HYA22 at chromosomal 3p22. 3 region in early and late-onset breast carcinoma: clinical and prognostic significance. Cancer Sci. 2008; 99: 1984-91.
9. Ghosh A, Ghosh S, Maiti GP, et al. Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance. Cancer Sci. 2010; 101: 1511-20.
10. Smyth EF, Sharma A, Sivarajasingham N, et al. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer. Dis Colon Rectum. 2004; 47: 2086-91.
11. Ju W, Park HM, Lee SN, et al. Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma. J Obstet Gynaecol Res. 2006; 32: 454-60.
12. Ide T, Kitajima Y, Ohtaka K, et al. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep. 2008; 19: 1571-6.
13. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107: 6982-7.
14. Duriseti S, Winnard PT Jr, Mironchik Y, et al. HOXA5 regulates hMLH1 expression in breast cancer cells. Neoplasia. 2006; 8: 250-8.
15. Nakamura H, Tanimoto K, Hiyama K, et al. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. Oncogene. 2008; 27: 4200-9.
16. Edwards RA, Witherspoon M, Wang K, et al. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res. 2009; 69: 6423-9.
17. Kondo E, Furukawa T, Yoshinaga K, et al. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol. 2000; 17: 535-41.
18. Tomaszewska R, Okoń K, Stachura J. Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features. Pol J Pathol. 2003; 54: 31-7.
19. Maple JT, Smyrk TC, Boardman LA, et al. Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancreatology. 2005; 5: 220-7.
20. Bergmann F, Aulmann S, Wente MN, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. 2006; 59: 580-4.
21. Nakata B, Wang YQ, Yashiro M, et al. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep. 2003; 10: 997-1000.
22. LaConti JJ, Shivapurkar N, Preet A, et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One. 2011; 6: e20687.
23. Catto JW, Xinarianos G, Burton JL, et al. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003; 105: 484-90.
24. Lazaris AC, Zarogiannos A, Kavantzas N, et al. MLH1 mismatch repair gene product is associated with apoptotic potential of urothelial bladder carcinomas. Anticancer Res. 2006; 26: 1535-42.
25. Vilar E, Scaltriti M, Balmaña J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 2008; 99: 1607-12.
26. Ding X, Mohd AB, Huang Z, et al. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer. 2009; 101: 269-77.
27. Collins SL, Hervé R, Keevil CW, et al. Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. PLoS One. 2011; 6: e28123.
28. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
29. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120: 1046-54.
30. Ali S, Banerjee S, Logna F, et al. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol. 2012; 227: 3373-80.
31. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104: 16170-5.
32. Perini MV, Montagnini AL, Jukemura J, et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford). 2008; 10: 356-62.
33. Sahin TT, Fujii T, Kanda M, et al. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas. 2011; 40: 1029-33.
34. Ansari D, Rosendahl A, Elebro J, et al. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011; 98: 1041-55.
35. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010; 126: 73-80.